Preclinical validation of a novel cancer immunotherapeutic

点击翻译按钮获取中文摘要

Epsilogen (formerly IGEM Therapeutics) is developing a novel HER2-targeted antibody EPS 201, selected on a number of key attributes that sets it apart from marketed competitors. The project seeks to move EPS 201 closer to the clinic through development of product quality assays, _in vivo_ models for GLP toxicology and efficacy, and a manufacturing cell line for progression to GMP. IgE provides a completely unique anti-cancer mode of action which enables our products to be clearly differentiated from IgG-based therapies.